summary,summary_detail,id,guidislink,links,url,date,published_parsed,title,title_detail,ticker,source,text,Year,Month,Day,Weekday,text_length,word_count,title_length,title_word_count
"Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': ""Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.""}",99e030f1-3faf-357e-934c-65b39fcba011,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/m/99e030f1-3faf-357e-934c-65b39fcba011/bristol-myers-slumps-on-heart.html?.tsrc=rss'}]",https://finance.yahoo.com/m/99e030f1-3faf-357e-934c-65b39fcba011/bristol-myers-slumps-on-heart.html?.tsrc=rss,2025-04-14 22:15:55,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=14, tm_hour=22, tm_min=15, tm_sec=55, tm_wday=0, tm_yday=104, tm_isdst=0)",Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It'}",BMY,Yahoo Finance,"Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study.",2025,4,14,0,212,32,72,12
"PRINCETON, N.J., April 14, 2025--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'PRINCETON, N.J., April 14, 2025--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial'}",8f83e4e1-a333-3711-b189-23c1561361a3,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/bristol-myers-squibb-provides-phase-201500074.html?.tsrc=rss'}]",https://finance.yahoo.com/news/bristol-myers-squibb-provides-phase-201500074.html?.tsrc=rss,2025-04-14 20:15:00,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=14, tm_hour=20, tm_min=15, tm_sec=0, tm_wday=0, tm_yday=104, tm_isdst=0)",Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial'}",BMY,Yahoo Finance,"Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial PRINCETON, N.J., April 14, 2025--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial",2025,4,14,0,164,24,65,10
"Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.'}",a98e29b0-e9fd-3b81-9c55-cefa62b5cedb,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-130013918.html?.tsrc=rss'}]",https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-130013918.html?.tsrc=rss,2025-04-14 13:00:13,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=14, tm_hour=13, tm_min=0, tm_sec=13, tm_wday=0, tm_yday=104, tm_isdst=0)",Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know'}",BMY,Yahoo Finance,"Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",2025,4,14,0,241,41,97,15
The approval is anchored in the outcomes from the open-label randomised Phase III CheckMate-9DW trial.,"{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'The approval is anchored in the outcomes from the open-label randomised Phase III CheckMate-9DW trial.'}",b4582213-58a7-3b55-aeab-6fc7ee099799,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://www.pharmaceutical-technology.com/news/bms-opdivo-approved-us/?.tsrc=rss'}]",https://www.pharmaceutical-technology.com/news/bms-opdivo-approved-us/?.tsrc=rss,2025-04-14 08:32:17,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=14, tm_hour=8, tm_min=32, tm_sec=17, tm_wday=0, tm_yday=104, tm_isdst=0)",BMS’ Opdivo combo approved in US for hepatocellular carcinoma,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'BMS’ Opdivo combo approved in US for hepatocellular carcinoma'}",BMY,Yahoo Finance,BMS’ Opdivo combo approved in US for hepatocellular carcinoma The approval is anchored in the outcomes from the open-label randomised Phase III CheckMate-9DW trial.,2025,4,14,0,164,24,61,9
Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level.,"{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level.'}",b74014e2-2a09-3691-abe1-a80e56248913,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/m/b74014e2-2a09-3691-abe1-a80e56248913/biotech-stock-bounces-from.html?.tsrc=rss'}]",https://finance.yahoo.com/m/b74014e2-2a09-3691-abe1-a80e56248913/biotech-stock-bounces-from.html?.tsrc=rss,2025-04-11 20:09:17,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=11, tm_hour=20, tm_min=9, tm_sec=17, tm_wday=4, tm_yday=101, tm_isdst=0)","Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market","{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market'}",BMY,Yahoo Finance,"Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level.",2025,4,11,4,199,32,80,11
"We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and big […]","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and big […]'}",d017688f-3c9f-3176-a58f-4917c997cdbd,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-195824477.html?.tsrc=rss'}]",https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-195824477.html?.tsrc=rss,2025-04-11 19:58:24,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=11, tm_hour=19, tm_min=58, tm_sec=24, tm_wday=4, tm_yday=101, tm_isdst=0)",Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires?,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires?'}",BMY,Yahoo Finance,"Is Bristol-Myers Squibb Company (BMY) One of the Best Medical Stocks to Buy According to Billionaires? We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and big […]",2025,4,11,4,453,72,102,16
"PRINCETON, N.J., April 11, 2025--U.S. Food and Drug Administration Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'PRINCETON, N.J., April 11, 2025--U.S. Food and Drug Administration Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma'}",127a3256-0cc8-3880-9822-1749583a87c5,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/u-food-drug-administration-approves-194900963.html?.tsrc=rss'}]",https://finance.yahoo.com/news/u-food-drug-administration-approves-194900963.html?.tsrc=rss,2025-04-11 19:49:00,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=11, tm_hour=19, tm_min=49, tm_sec=0, tm_wday=4, tm_yday=101, tm_isdst=0)",U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma'}",BMY,Yahoo Finance,"U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma PRINCETON, N.J., April 11, 2025--U.S. Food and Drug Administration Approves Opdivo plus Yervoy as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma",2025,4,11,4,347,44,170,21
"Bristol-Myers Squibb (BMY) investors will be focused on the trajectory of Cobenfy, its schizophrenia","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol-Myers Squibb (BMY) investors will be focused on the trajectory of Cobenfy, its schizophrenia'}",3e435ddf-0cf2-393d-a629-d136670995e1,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/bristol-myers-squibb-investors-likely-191255196.html?.tsrc=rss'}]",https://finance.yahoo.com/news/bristol-myers-squibb-investors-likely-191255196.html?.tsrc=rss,2025-04-11 19:12:55,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=11, tm_hour=19, tm_min=12, tm_sec=55, tm_wday=4, tm_yday=101, tm_isdst=0)","Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says","{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says'}",BMY,Yahoo Finance,"Bristol-Myers Squibb Investors Likely to Focus on Performance of New Schizophrenia Therapy, UBS Says Bristol-Myers Squibb (BMY) investors will be focused on the trajectory of Cobenfy, its schizophrenia",2025,4,11,4,201,28,100,14
"Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.'}",a984381c-41cb-3c58-8c9c-de9b5fc8dddd,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/3-value-stocks-doghouse-130156319.html?.tsrc=rss'}]",https://finance.yahoo.com/news/3-value-stocks-doghouse-130156319.html?.tsrc=rss,2025-04-11 13:01:56,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=11, tm_hour=13, tm_min=1, tm_sec=56, tm_wday=4, tm_yday=101, tm_isdst=0)",3 Value Stocks in the Doghouse,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': '3 Value Stocks in the Doghouse'}",BMY,Yahoo Finance,"3 Value Stocks in the Doghouse Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",2025,4,11,4,351,63,30,6
Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.,"{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': ""Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.""}",5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s%26p%2C-dow-jones-pharma-names.html?.tsrc=rss'}]",https://finance.yahoo.com/m/5788e167-ba2e-3f2d-8e9e-4bfb72e0e2c1/s%26p%2C-dow-jones-pharma-names.html?.tsrc=rss,2025-04-10 16:58:23,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=10, tm_hour=16, tm_min=58, tm_sec=23, tm_wday=3, tm_yday=100, tm_isdst=0)","S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash","{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': ""S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash""}",BMY,Yahoo Finance,"S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash Pharma stocks tumbled Thursday after the Trump administration said the delay for reciprocal tariffs doesn't apply to sector-specific tariffs.",2025,4,10,3,215,32,73,13
"Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.'}",c5749d3e-8498-3b6a-90f0-edbbd55a2e3f,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/zacks-analyst-blog-highlights-pacira-090000796.html?.tsrc=rss'}]",https://finance.yahoo.com/news/zacks-analyst-blog-highlights-pacira-090000796.html?.tsrc=rss,2025-04-10 09:00:00,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=10, tm_hour=9, tm_min=0, tm_sec=0, tm_wday=3, tm_yday=100, tm_isdst=0)","The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb","{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb'}",BMY,Yahoo Finance,"The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.",2025,4,10,3,234,31,116,15
"In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from the preceding trading day.","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from the preceding trading day.'}",351c8ca1-3a7d-3b4a-a05d-0cd36dda4031,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/heres-why-bristol-myers-squibb-214505812.html?.tsrc=rss'}]",https://finance.yahoo.com/news/heres-why-bristol-myers-squibb-214505812.html?.tsrc=rss,2025-04-09 21:45:05,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=21, tm_min=45, tm_sec=5, tm_wday=2, tm_yday=99, tm_isdst=0)",Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': ""Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today""}",BMY,Yahoo Finance,"Here's Why Bristol Myers Squibb (BMY) Gained But Lagged the Market Today In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $53.78, denoting a +1.34% change from the preceding trading day.",2025,4,9,2,215,36,72,12
"Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 3.3% and th","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 3.3% and th'}",a9506196-aa66-3999-b9b1-722dfa8e37b4,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/sector-health-care-stocks-gain-200231910.html?.tsrc=rss'}]",https://finance.yahoo.com/news/sector-health-care-stocks-gain-200231910.html?.tsrc=rss,2025-04-09 20:02:31,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=20, tm_min=2, tm_sec=31, tm_wday=2, tm_yday=99, tm_isdst=0)",Sector Update: Health Care Stocks Gain Late Afternoon,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Sector Update: Health Care Stocks Gain Late Afternoon'}",BMY,Yahoo Finance,"Sector Update: Health Care Stocks Gain Late Afternoon Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 3.3% and th",2025,4,9,2,154,25,53,8
"We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other profitable dividend stocks. Amid growing concerns about economic growth and President Trump’s tariffs, investors have been seeking safer investment options. […]","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other profitable dividend stocks. Amid growing concerns about economic growth and President Trump’s tariffs, investors have been seeking safer investment options. […]'}",b025dbe8-8777-3343-a1c7-03feeb2a4bb0,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-193753036.html?.tsrc=rss'}]",https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-193753036.html?.tsrc=rss,2025-04-09 19:37:53,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=19, tm_min=37, tm_sec=53, tm_wday=2, tm_yday=99, tm_isdst=0)",Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in'}",BMY,Yahoo Finance,"Bristol-Myers Squibb Company (BMY): Among the High Growth Dividend Paying Stocks to Invest in We recently published a list of the 10 High Growth Dividend Paying Stocks to Invest in. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other profitable dividend stocks. Amid growing concerns about economic growth and President Trump’s tariffs, investors have been seeking safer investment options. […]",2025,4,9,2,457,70,93,14
"Bristol-Myers Squibb (NYSE:BMY) recently received FDA approval for the combination therapy of Opdivo and Yervoy, significantly enhancing its immunotherapy portfolio. Despite this positive development, the company's share price fell by 7% over the last quarter. This decline occurred in the backdrop of a broader market downturn, where major indices, like the S&amp;P 500, experienced a 12% drop due to escalating trade tensions and tariff announcements. BMY’s stock performance, influenced by regional...","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': ""Bristol-Myers Squibb (NYSE:BMY) recently received FDA approval for the combination therapy of Opdivo and Yervoy, significantly enhancing its immunotherapy portfolio. Despite this positive development, the company's share price fell by 7% over the last quarter. This decline occurred in the backdrop of a broader market downturn, where major indices, like the S&amp;P 500, experienced a 12% drop due to escalating trade tensions and tariff announcements. BMY’s stock performance, influenced by regional...""}",39c8b619-0474-3e6d-abd4-12782e2d264f,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-175017672.html?.tsrc=rss'}]",https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-175017672.html?.tsrc=rss,2025-04-09 17:50:17,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=17, tm_min=50, tm_sec=17, tm_wday=2, tm_yday=99, tm_isdst=0)",Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy'}",BMY,Yahoo Finance,"Bristol-Myers Squibb (NYSE:BMY) Achieves Early FDA Approval for Opdivo Plus Yervoy Therapy Bristol-Myers Squibb (NYSE:BMY) recently received FDA approval for the combination therapy of Opdivo and Yervoy, significantly enhancing its immunotherapy portfolio. Despite this positive development, the company's share price fell by 7% over the last quarter. This decline occurred in the backdrop of a broader market downturn, where major indices, like the S&amp;P 500, experienced a 12% drop due to escalating trade tensions and tariff announcements. BMY’s stock performance, influenced by regional...",2025,4,9,2,595,83,90,12
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.,"{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.'}",c8500527-c498-301b-a71b-4f6b1278536a,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/biotech-stock-roundup-pcrx-patent-174500051.html?.tsrc=rss'}]",https://finance.yahoo.com/news/biotech-stock-roundup-pcrx-patent-174500051.html?.tsrc=rss,2025-04-09 17:45:00,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=17, tm_min=45, tm_sec=0, tm_wday=2, tm_yday=99, tm_isdst=0)","Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More","{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More'}",BMY,Yahoo Finance,"Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.",2025,4,9,2,172,30,77,15
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.,"{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.'}",b69de891-a682-3514-9026-49aecd247e9c,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/bmy-gets-fda-nod-label-174400443.html?.tsrc=rss'}]",https://finance.yahoo.com/news/bmy-gets-fda-nod-label-174400443.html?.tsrc=rss,2025-04-09 17:44:00,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=17, tm_min=44, tm_sec=0, tm_wday=2, tm_yday=99, tm_isdst=0)",BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo'}",BMY,Yahoo Finance,BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.,2025,4,9,2,203,32,64,12
"The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date. The approval is based on the Chec","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date. The approval is based on the Chec'}",1ad8525a-1718-39b9-8d1c-219627c68cb0,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/fda-approves-bristol-myers-opdivo-145853592.html?.tsrc=rss'}]",https://finance.yahoo.com/news/fda-approves-bristol-myers-opdivo-145853592.html?.tsrc=rss,2025-04-09 14:58:53,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=14, tm_min=58, tm_sec=53, tm_wday=2, tm_yday=99, tm_isdst=0)",FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': ""FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients""}",BMY,Yahoo Finance,"FDA Approves Bristol Myers' Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The approval comes ahead of over two months of the June 23, 2025, Prescription Drug User Fee Act goal date. The approval is based on the Chec",2025,4,9,2,594,89,93,13
"(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O","{'type': 'text/html', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': '(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O'}",fd61768e-7394-3f61-9a81-b80a31509cd1,False,"[{'rel': 'alternate', 'type': 'text/html', 'href': 'https://finance.yahoo.com/news/trump-says-pharmaceutical-tariffs-coming-094047688.html?.tsrc=rss'}]",https://finance.yahoo.com/news/trump-says-pharmaceutical-tariffs-coming-094047688.html?.tsrc=rss,2025-04-09 09:40:47,"time.struct_time(tm_year=2025, tm_mon=4, tm_mday=9, tm_hour=9, tm_min=40, tm_sec=47, tm_wday=2, tm_yday=99, tm_isdst=0)",Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’,"{'type': 'text/plain', 'language': None, 'base': 'https://feeds.finance.yahoo.com/rss/2.0/headline?s=BMY&region=US&lang=en-US', 'value': 'Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’'}",BMY,Yahoo Finance,"Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’ (Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.President Donald Trump said his long-promised tariffs on pharmaceutical drugs will be coming soon, the latest signal that he plans to press ahead with more sectoral tariffs despite market fallout from his global levies.“We are going to be announcing very shortly a major tariff on pharmaceuticals,” Trump said Tuesday at a fundraising gala for House Republicans, without providing details on the planned levy.“O",2025,4,9,2,556,84,55,7
